ArticleAging clinical and experimental research2025
The associations between cerebral microhemorrhages and cognitive decline across Alzheimer's continuum.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the associations between cerebral microhemorrhages (CMH) and cognitive decline across the Alzheimer's dementia continuum.
methodsUsing the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, we studied 619 participants, categorized into 221 cognitively normal (CN) participants, 281 patients with mild cognitive impairment (MCI), and 117 patients with Alzheimer's disease (AD). CMH prevalence and distribution were determined using T2-weighted magnetic resonance imaging (MRI), focusing on the frontal, occipital, and parietal subcortical regions of interest (ROIs).Clinical dementia rating scale sum of boxes (CDR-SB) and mini-mental state examination (MMSE) were used for diagnosis and composite cognitive scores regarding visuospatial abilities, language, memory, and executive functions were used as outcome variables. Age, gender, and APOE ε4 positivity status were used as covariates.
resultsThe AD group displayed significantly elevated tau and P-tau levels compared to MCI and CN groups (p < 0.001). APOE ε4 positivity was 67.5% in the AD group, surpassing the 50.2% in MCI and 29% in CN individuals (p < 0.001). Cognitive assessments revealed that the AD group's CDR-SB score and MMSE both significantly differed from these scores in the MCI and CN groups (p < 0.001). Overall, CMH prevalence was 27.7%, with a predominant distribution in the frontal subcortical ROIs. MCI subjects with CMH showed notably diminished ADNI Visuospatial Composite Scores compared to those without CMH. Age significantly predicted CMH in CN and MCI (p < 0.05). In AD participants, APOE ε4 heterozygotes (p = 0.02) and homozygotes (p = 0.01) hadincreased CMH likelihood.
conclusionCMHs are significantly associated with cognitive decline in patients with MCI. This association is more prominent in regard to the decline in visuospatial abilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.